Talk:7-OH
| 7-OH | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||
| Common names | 7-OH, 7-Hydroxymitragynine, 7-OHM | ||||||||||||||||||||||||||||||||
| Substitutive name | 7-Hydroxymitragynine | ||||||||||||||||||||||||||||||||
| Systematic name | Methyl (2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,6,7,7a,12b-hexahydro-1H-indolo[2,3-a]quinolizine-2-carboxylate | ||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||
| Psychoactive class | Opioid | ||||||||||||||||||||||||||||||||
| Chemical class | Indole alkaloid | ||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
7-Hydroxymitragynine (also known as 7-OH) is a potent psychoactive terpenoid indole alkaloid derived from the plant Mitragyna speciosa (commonly known as kratom). It is classified as an atypical opioid substance of the alkaloid class. The mechanism of action is primarily mediated through its high-affinity binding activity as a partial agonist at the mu-opioid receptor.
While naturally occurring in very small quantities within fresh kratom leaves, 7-hydroxymitragynine is also generated in vivo as a major active metabolite of mitragynine via hepatic cytochrome P450 (CYP3A4) metabolism.[1] In recent years, isolated and concentrated forms of 7-OH have emerged in the botanical supplement market as standalone products, separate from traditional raw plant material.
In contrast to conventional, full-agonist opioids like morphine or oxycodone, 7-hydroxymitragynine acts as a G-protein-biased agonist at the mu-opioid receptor. This signaling bias means it preferentially activates pathways responsible for analgesia while recruiting β-arrestin-2 to a significantly lesser degree, which is hypothesized in literature to result in a lower risk of severe respiratory depression and constipation relative to its analgesic potency.[2]
Subjective effects include pain relief, sedation, physical euphoria, cognitive euphoria, anxiety suppression, and relaxation. At lower doses, some users report a mild, paradoxical background stimulation, though typical doses are overwhelmingly sedating and opioid-like in nature.
Unlike conventional opioids, its status as a partial agonist introduces a ceiling effect on certain physiological side effects, though adverse psychological and physical reactions such as severe nausea, dizziness, itching, constipation, and physical dependence are highly possible with sustained consumption.
It is highly advised to use harm reduction practices if using this substance.
History and culture
7-Hydroxymitragynine was first isolated from Mitragyna speciosa in 1994 by a team of Japanese researchers seeking to map the diverse alkaloid profile of the plant.[3] For decades, it remained primarily a subject of academic interest within phytochemistry and neuropharmacology. Early studies noted that despite its low concentration in raw leaf material (often less than 0.05% of the total alkaloid content), its exceptional potency at opioid receptors contributed significantly to the plant's overall therapeutic and psychoactive profile.
Following the global commercial growth of the kratom industry throughout the 2010s and 2020s, extraction methodologies advanced significantly. By the mid-2020s, specialized extract products specifically standardized for high concentrations of 7-OH (often sold in tablet or liquid form) entered the botanical marketplace. This shift transformed 7-OH from an obscure alkaloid into a prominent, distinct commodity within consumer markets, prompting ongoing discussions regarding public safety, industry regulation, and consumer access.
Common names
7-Hydroxymitragynine is commonly referred to in online communities and markets as: 7-OH, 7-hydroxy, or simply OH.
Chemistry
7-Hydroxymitragynine is a terpenoid indole alkaloid. Structurally, it is a chemical derivative of mitragynine, featuring a core indole nucleus substituted at the C7 position with a hydroxyl (-OH) functional group. It shares structural similarities to the corynantheine class of alkaloids, containing a monoterpene unit integrated into its polycyclic ring framework.
The chemical formula for 7-hydroxymitragynine is C₂₃H₃₀N₂O₅, with a molecular weight of 414.50 g/mol. The presence of the C7 hydroxyl group significantly alters the lipophilicity and target-binding characteristics of the molecule compared to mitragynine, dramatically increasing its affinity for opioid receptor targets.
Pure 7-OH isolates typically present as an amorphous or crystalline powder that is highly sensitive to degradation when exposed to heat, strong UV light, or highly alkaline solutions over extended periods.
Pharmacology
7-Hydroxymitragynine acts primarily as a high-affinity partial agonist at the $\mu$-opioid receptor ($\mu$-OR). In functional assays, it demonstrates an analgesic potency significantly higher than mitragynine and comparable or superior to morphine when evaluated in animal models.[4]
While it acts as an agonist at $\mu$-opioid receptors, it exhibits competitive antagonist properties at the $\kappa$-opioid ($\kappa$-OR) and $\delta$-opioid ($\delta$-OR) receptors. This multi-receptor profile differs fundamentally from classical full agonists, which typically activate all three sub-types to varying degrees or induce heavy down-regulation across receptors.
Crucially, 7-OH behaves as a biased agonist. It shows a strong preference for activating the G-protein signaling pathway while inducing minimal recruitment of $\beta$-arrestin-2. In conventional opioid pharmacology, $\beta$-arrestin recruitment is directly implicated in the development of severe respiratory depression, profound tolerance, and significant gastrointestinal slowing. The relative absence of this pathway activation characterizes the unique therapeutic index under investigation in modern ethnobotanical research.
Subjective effects
The headspace of 7-hydroxymitragynine is typically described as deeply sedating, physically comforting, and analgesic. It lacks the intense cognitive impairment or "mental cloudiness" associated with high doses of conventional medical opioids, maintaining a distinct level of clear-headedness alongside severe physical relaxation.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
-
- Pain relief - 7-OH produces strong, dose-dependent systemic analgesia, dampening both chronic and acute physical discomfort.
- Sedation - At common to strong doses, this substance induces a heavy state of physical relaxation, frequently accompanied by lethargy and a desire to remain stationary.
- Spontaneous bodily sensations - The "body high" is characterized by an all-encompassing sensation of physical warmth, comfort, and heaviness that spreads across the torso and limbs during the onset phase.
- Nausea - Common at higher doses or when combined with movement. This effect can be mitigated by remaining supine or using the substance on an empty stomach.
- Itchiness - A common side effect resulting from opioid-induced histamine release, presenting as a generalized, mild to moderate itch across the skin.
- Pupil constriction - Induces noticeable miosis (constriction of the pupils) that persists throughout the duration of the experience.
- Constipation - Slows gastrointestinal motility, though to a reportedly lesser degree than equivalent doses of classical full-agonist opioids.
- Dizziness - Often described as the "wobbles" if over-consumed, presenting as a minor loss of motor coordination or spatial disorientation when moving the eyes rapidly.
Cognitive effects 
-
- Cognitive euphoria - A distinct sense of emotional comfort, contentment, and well-being, though generally less intense or forced than that of full-agonist pharmaceuticals.
- Anxiety suppression - Strongly blunts emotional distress, overthinking, and somatic symptoms of anxiety.
- Thought deceleration - Quiets internal monologues and slows down rapid ideation, contributing to the overall sedating properties of the compound.
- Dreaminess - At high doses, users may enter a state resembling hypnagogia, experiencing vivid, brief daydreams or drift-states while resting with eyes closed.
Combination effects
- Alcohol - This combination is highly dangerous. Alcohol potentiates the central nervous system (CNS) depressant qualities of 7-OH, greatly increasing the risk of severe sedation, heavy respiratory depression, blackouts, and severe nausea. It should be strictly avoided.
- Benzodiazepines - Concomitant use with benzodiazepines exponentially intensifies CNS depression. This mixture drastically elevates the risk of accidental overdose, profound respiratory failure, coma, and death.
- Cannabis - Cannabis can potentiate the physical euphoria and sedation of 7-OH while introducing a stronger cognitive element. It may also increase the likelihood of dry mouth and drowsiness.
- Stimulants - Combining 7-OH with stimulants (such as caffeine or amphetamines) can mask the sedative properties of the alkaloid, potentially leading to accidental overconsumption once the stimulant wears off. It may also place additional stress on the cardiovascular system.
Experience reports
There are currently 0 anecdotal reports which describe the effects of this compound within our experience index.
Toxicity and harm potential
Numerous preliminary animal models indicate that 7-hydroxymitragynine possesses a more favorable toxicity profile and a wider therapeutic index than classical $\mu$-opioid full agonists, primarily due to its G-protein signaling bias. However, it is a highly potent psychoactive compound capable of inducing severe physical and psychological adverse effects if misused.
Overconsumption can lead to profound physiological distress characterized by severe vertigo, persistent vomiting, extreme lethargy, and hypotension. While respiratory depression is significantly less pronounced than with full agonists, dangerous respiratory depression can still occur, particularly when pure isolates are consumed in massive excess or mixed with other central nervous system depressants.
Sustained use of 7-OH carries a high risk of developing physical tolerance, psychological addiction, and a distinct withdrawal syndrome upon cessation.
It is strongly advised to use harm reduction practices if using this substance. These include:
- Utilizing accurate scales or verified mg-standardized products to prevent accidental over-dosing.
- Strictly avoiding the combination of this substance with any other downers, alcohol, or prescription sedatives.
- Implementing mandatory consecutive rest days between uses to prevent the rapid onset of physical dependence and severe withdrawal symptoms.
Dependence and abuse potential
7-Hydroxymitragynine possesses a distinct high dependence potential relative to raw leaf kratom due to its rapid onset and high affinity for the mu-opioid receptor. Chronic administration results in down-regulation of opioid signaling pathways over time, building a rapid physical tolerance.
Abrupt cessation after prolonged use triggers a classic opioid withdrawal syndrome. Symptoms include severe restlessness, insomnia, muscle aches, rhinorrhea, sweating, anxiety, and intense drug cravings.
Legal status
The legal status of 7-hydroxymitragynine is highly variable globally and often tied directly to the legal framework governing *Mitragyna speciosa* (kratom) or its specific alkaloid derivatives.
- United Kingdom: Illegal to manufacture, import, or distribute under the Psychoactive Substances Act 2016.
- United States: Not explicitly listed on the federal Controlled Substances Act schedule. However, it is subject to state-level restrictions where kratom or its alkaloids have been banned (e.g., Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin). States operating under the Kratom Consumer Protection Act (KCPA) may impose age restrictions or strict labeling requirements on products containing standardized levels of 7-OH.
See also
External links
References
- ↑ Kruegel, A. C., Uprety, R., Grinnell, S. G., Kancko, Y., Majumdar, S., Sames, D. (2019). "7-Hydroxymitragynine Is an Active Metabolite of Mitragyna speciosa Alkaloids and Mediates Opioid Receptor-Like Behavioral Effects". Journal of the American Chemical Society. 141 (35): 13849–13858. doi:10.1021/jacs.9b05346.
- ↑ Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M., Majumdar, S. (2016). "Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Receptor Biased Agonists: Modulation of Analgesia and Respiratory Depression". Journal of Medicinal Chemistry. 59 (18): 8381–8397. doi:10.1021/acs.jmedchem.6b00748.
- ↑ Ponglux, D., Wongseripipatana, S., Takayama, H., Aimi, N. (1994). "A New Indole Alkaloid, 7-Hydroxymitragynine, from Mitragyna speciosa in Thailand". Chemical and Pharmaceutical Bulletin. 42 (9): 1960–1962. doi:10.1248/cpb.42.1960.
- ↑ Matsumoto, K., Horie, S., Ishikawa, H., Takayama, H., Aimi, N., Watanabe, K. (2004). "Antinociceptive effect of 7-hydroxymitragynine in mice: Oral administration and involvement of opioid receptor mechanisms". Life Sciences. 74 (17): 2143–2155. doi:10.1016/j.lfs.2003.09.031.